Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies
Author Contributions
Funding
Conflicts of Interest
References
- Reaven, G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37, 1595–1607. [Google Scholar] [CrossRef]
- Kahn, R.; Buse, J.; Ferrannini, E.; Stern, M. The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28, 2289–2304. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Einhorn, D.; Reaven, G.M.; Cobin, R.H.; Ford, E.; Ganda, O.P.; Handelsman, Y.; Hellman, R.; Jellinger, P.S.; Kendall, D.; Krauss, R.M.; et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr. Pr. 2003, 9, 237–252. [Google Scholar]
- Ramzan, F.; Vickers, M.; Mithen, R. Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review. Int. J. Mol. Sci. 2021, 22, 5047. [Google Scholar] [CrossRef] [PubMed]
- Abate, N.; Sallam, H.S.; Rizzo, M.; Nikolic, D.; Obradovic, M.; Bjelogrlic, P.; Isenovic, E.R. Resistin: An inflamma-tory cytokine. Role in cardiovascular diseases, diabetes and the metabolic syndrome. Curr. Pharm. Des. 2014, 20, 4961–4969. [Google Scholar] [CrossRef]
- Rizvi, A.A. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syn-drome: Emerging concepts. Am. J. Med. Sci. 2009, 338, 310–318. [Google Scholar] [CrossRef]
- Berneis, K.K.; Krauss, R.M. Metabolic origins and clinical significance of LDL heterogeneity. J. Lipid Res. 2002, 43, 1363–1379. [Google Scholar] [CrossRef] [Green Version]
- Rizzo, M.; Berneis, K. Who needs to care about small, dense low-density lipoproteins? Int. J. Clin. Pr. 2007, 61, 1949–1956. [Google Scholar] [CrossRef]
- Berneis, K.; Rizzo, M.; Hersberger, M.; Rini, G.B.; Di Fede, G.; Pepe, I.; Spinas, G.A.; Carmina, E. Atherogenic forms of dyslipidemia in women with polycystic ovary syndrome. Int. J. Clin. Pr. 2009, 63, 56–62. [Google Scholar] [CrossRef]
- Rizzo, M.; Pernice, V.; Frasheri, A.; Berneis, K. Atherogenic lipoprotein phenotype and LDL size and sub-classes in patients with peripheral arterial disease. Atherosclerosis 2008, 197, 237–241. [Google Scholar] [CrossRef]
- Rizzo, M.; Berneis, K.; Altinova, A.E.; Toruner, F.B.; Akturk, M.; Ayvaz, G.; Rini, G.B.; Spinas, G.A.; Arslan, M. Athero-genic lipoprotein phenotype and LDL size and subclasses in women with gestational diabetes. Diabet Med. 2008, 25, 1406–1411. [Google Scholar] [CrossRef] [PubMed]
- Goedecke, J.H.; Utzschneider, K.; Faulenbach, M.V.; Rizzo, M.; Berneis, K.; Spinas, G.A.; Dave, J.; Levitt, N.S.; Lambert, E.; Olsson, T.; et al. Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism 2010, 59, 1341–1350. [Google Scholar] [CrossRef] [PubMed]
- Rizzo, M.; Spinas, G.A.; Cesur, M.; Ozbalkan, Z.; Rini, G.B.; Berneis, K. Atherogenic lipoprotein phenotype and LDL size and subclasses in drug-naïve patients with early rheumatoid arthritis. Atherosclerosis 2009, 207, 502–506. [Google Scholar] [CrossRef] [PubMed]
- Corrado, E.; Rizzo, M.; Coppola, G.; Muratori, I.; Carella, M.; Novo, S. Endothelial dysfunction and carotid le-sions are strong predictors of clinical events in patients with early stages of atherosclerosis: A 24-month follow-up study. Coron. Artery. Dis. 2008, 19, 139–144. [Google Scholar] [CrossRef]
- Rizzo, M.; Rizvi, A.A.; Patti, A.M.; Nikolic, D.; Giglio, R.V.; Castellino, G.; Li Volti, G.; Caprio, M.; Montalto, G.; Provenzano, V.; et al. Liraglutide improves metabolic parameters and carotid inti-ma-media thickness in diabetic patients with the metabolic syndrome: An 18-month prospective study. Cardiovasc. Diabetol. 2016, 15, 162. [Google Scholar] [CrossRef] [Green Version]
- Patti, A.M.; Nikolic, D.; Magan-Fernandez, A.; Giglio, R.V.; Castellino, G.; Chianetta, R.; Citarrella, R.; Corrado, E.; Provenzano, F.; Provenzano, V.; et al. Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabe-tes: An 8-month prospective study. Diabetes Res. Clin. Pr. 2019, 149, 163–169. [Google Scholar] [CrossRef]
- Nikolic, D.; Giglio, R.V.; Rizvi, A.A.; Patti, A.M.; Montalto, G.; Maranta, F.; Cianflone, D.; Stoian, A.P.; Rizzo, M. Lirag-lutide reduces carotid intima-media thickness by reducing small dense low-density lipoproteins in a re-al-world setting of patients with type 2 diabetes: A novel anti-atherogenic effect. Diabetes 2021, 12, 261–274. [Google Scholar]
- Nauck, M.A.; Quast, D.R.; Wefers, J.; Pfeiffer, A.F. The Evolving Story of Incretins (GIP and GLP-1) in Metabolic and Cardiovascular Disease: A Pathophysiological Update. Diabetes Obes. Metab. 2021. [Google Scholar] [CrossRef]
- Ceriello, A.; Stoian, A.P.; Rizzo, M. COVID-19 and diabetes management: What should be considered? Diabetes Res. Clin. Pr. 2020, 163, 108151. [Google Scholar] [CrossRef]
- Tessier, C.M.; Kokkinos, A.; Mingrone, G.; Koliaki, C.; Zierath, J.R.; Mantzoros, C.S. COVID-19 editorial: Mechanistic links and therapeutic challenges for metabolic diseases one year into the COVID-19 pandemic. Metabolism 2021, 119, 154769. [Google Scholar] [CrossRef]
- Stoian, A.P.; Banerjee, Y.; Rizvi, A.A.; Rizzo, M. Diabetes and the COVID-19 Pandemic: How Insights from Re-cent Experience Might Guide Future Management. Metab Syndr. Relat. Disord. 2020, 18, 173–175. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rizvi, A.A.; Stoian, A.P.; Rizzo, M. Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. Int. J. Mol. Sci. 2021, 22, 10038. https://doi.org/10.3390/ijms221810038
Rizvi AA, Stoian AP, Rizzo M. Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. International Journal of Molecular Sciences. 2021; 22(18):10038. https://doi.org/10.3390/ijms221810038
Chicago/Turabian StyleRizvi, Ali Abbas, Anca Pantea Stoian, and Manfredi Rizzo. 2021. "Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies" International Journal of Molecular Sciences 22, no. 18: 10038. https://doi.org/10.3390/ijms221810038